文献速递泌尿男性生殖肿瘤

分子亚型与非转移性去势抵抗性前列腺癌阿帕他胺疗效差异的关联

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · JAMA Oncol · 2021-01-01

本研究基于SPARTAN随机双盲3期试验的233例归档原发肿瘤样本,用人类外显子微阵列生成基因表达数据,分析基因组分类器(GC)评分及基底/管腔亚型与阿帕他胺+ADT疗效的关联。结果显示高GC评分者从阿帕他胺+ADT中MFS、OS、PFS2获益最大,管腔亚型患者MFS获益更显著,提示上述分型或可作为疗效生物标志物。

要点

  • 高GC评分(>0.6)患者阿帕他胺+ADT的MFS、OS、PFS2获益最大。
  • 管腔亚型患者阿帕他胺+ADT的MFS显著优于基底亚型。
  • GC评分与基底-管腔分型或有助于筛选早期强化治疗人群。

核心结论

  • GC评分与基底-管腔亚型或可作为nmCRPC患者对阿帕他胺+ADT反应的生物标志物。
  • 总体上阿帕他胺加ADT有益,但高风险与管腔亚型患者获益最大。

研究设计与样本

  • 基于SPARTAN随机双盲3期试验的队列研究,纳入233例归档原发肿瘤样本。
  • 用人类外显子微阵列生成基因表达数据,分析时间为2018年5月10日至2020年10月15日。
  • 患者按2:1随机接受阿帕他胺240 mg/d+ADT或安慰剂+ADT。

主要发现

  • 233例中116例(50%)GC评分高,152例(65%)为基底亚型,中位年龄73岁(范围49-91)。
  • 高GC评分者阿帕他胺+ADT对比安慰剂+ADT的MFS HR 0.21(95%CI 0.11-0.40,P<.001)。
  • 高GC评分者OS HR 0.52(95%CI 0.29-0.94,P=.03),PFS2 HR 0.39(95%CI 0.23-0.67,P=.001)。
  • 阿帕他胺+ADT组管腔vs基底亚型MFS HR 0.40(95%CI 0.18-0.91,P=.03),OS HR 0.50(95%CI 0.25-0.98,P=.04)。
  • 回归分析中管腔-基底评分与阿帕他胺+ADT组MFS相关(HR 2.65,95%CI 1.15-6.08,P=.02)。

关键数值与推荐

  • GC高评分定义为GC>0.6,低至平均为GC≤0.6。
  • 按GC评分和基底/管腔亚型分层,评估MFS、OS、PFS2。
  • 采用Cox比例风险回归与Kaplan-Meier分析。

临床怎么用

  • 可考虑检测归档肿瘤标本的GC评分以识别适合早期阿帕他胺强化治疗的nmCRPC患者。
  • 基底-管腔分型或可用于临床试验中筛选联合新药进一步强化治疗的人群。

局限性

  • 为基于SPARTAN试验归档样本的探索性生物标志物分析,样本量有限(233例)。
  • 部分亚组比较未达统计学显著(如阿帕他胺+ADT组PFS2的管腔vs基底比较P=.22)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is a need to identify prognostic biomarkers to guide treatment intensification in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). OBJECTIVE: To examine whether molecular subtypes predict response to apalutamide, using archived primary tumor samples from the randomized, double-blind, phase 3 SPARTAN trial. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, gene expression data from 233 archived samples from patients with nmCRPC enrolled in the SPARTAN trial were generated using a human exon microarray. The present analysis was conducted from May 10, 2018, to October 15, 2020. INTERVENTIONS: Patients were randomized (2:1) to apalutamide, 240 mg/d, with androgen deprivation therapy (apalutamide+ADT) or placebo+ADT. MAIN OUTCOMES AND MEASURES: Patients were stratified into high-risk and low-risk categories for developing metastases based on genomic classifier (GC) scores for high (GC >0.6) and low to average (GC≤0.6) and into basal and luminal subtypes; associations between these molecular subtypes and metastasis-free survival (MFS), overall survival (OS), and progression-free survival 2 (PFS2) were evaluated using Cox proportional hazards regression and Kaplan-Meier analysis. RESULTS: Median age of the 233 included patients was 73 (range, 49-91) years. A total of 116 of 233 patients (50%) in the SPARTAN biomarker subset had high GC scores. Although all patients receiving apalutamide+ADT had improved outcomes, having high GC scores was associated with the greatest improvement in MFS (hazard ratio [HR], 0.21; 95% CI, 0.11-0.40; P < .001), OS (HR, 0.52; 95% CI, 0.29-0.94; P = .03), and PFS2 (HR, 0.39; 95% CI, 0.23-0.67; P = .001) vs placebo+ADT. In total, 152 of 233 patients (65%) had the basal molecular subtype. Although there were no significant differences in MFS, PFS2, or OS between patients with the luminal vs basal subtype in the placebo+ADT arm, patients with the luminal subtype in the apalutamide+ADT arm had a significantly longer MFS (apalutamide+ADT: HR, 0.40; 95% CI, 0.18-0.91; P = .03; placebo+ADT: HR, 0.66; 95% CI, 0.33-1.31; P = .23) compared with patients with basal subtype; similar trends were observed for OS (apalutamide+ADT: HR, 0.50; 95% CI, 0.25-0.98; P = .04; placebo+ADT: HR, 0.78; 95% CI, 0.38-1.60; P = .50), and PFS2 (apalutamide+ADT: HR, 0.71; 95% CI, 0.42-1.22; P = .22; placebo+ADT: HR, 0.72; 95% CI, 0.38-1.39; P = .33). In regression analysis, the luminal-basal subtype score was significantly associated with MFS in patients receiving apalutamide+ADT (HR, 2.65; 95% CI, 1.15-6.08; P = .02), whereas GC score was significantly associated with MFS in placebo+ADT recipients (HR, 2.09; 95% CI, 1.02-4.27; P = .04). CONCLUSIONS AND RELEVANCE: The findings of this study suggest that the GC score and basal-luminal subtype derived from archived tumor specimens may be biomarkers of response to apalutamide+ADT in the nmCRPC setting. Although overall, the addition of apalutamide to ADT was beneficial, higher-risk and luminal subtypes appeared to benefit most. Obtaining GC scores may be useful for identifying patients for early treatment intensification with apalutamide, and basal-luminal subtyping may be a beneficial approach for patient selection for further treatment intensification in trials combining novel therapies with apalutamide.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Feng FY, Thomas S, Saad F, et al. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2021. PMID: 34081076. doi:10.1001/jamaoncol.2021.1463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。